Lamotrigine-induced Stevens-Johnson syndrome in a 25 year old lady

Hrishikesh Kashyapa*, Laxman Verma, Rupali B. Jadhav

Department of Pharmacology,
Dr. V. M. Govt. Medical College and Shri Chhatrapati Shivaji Maharaj Sarvopchar Rugnalaya, Solapur, Maharashtra, India

Received: 11 August 2016
Accepted: 15 September 2016

*Correspondence to:
Dr. Hrishikesh Kashyapa,
Email: hkashyapa@yahoo.co.in

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Stevens-Johnson syndrome (SJS) is an immune-complex mediated hypersensitivity reaction and has been linked as an adverse side effect to many drugs. This case is about a 25 year old woman who had lamotrigine-induced Stevens-Johnson syndrome which is known to occur but is rare. Lamotrigine, an anticonvulsive medication and also a commonly used mood stabilizer was prescribed to the patient to treat symptoms of anxiety and depression. The patient developed Stevens-Johnson syndrome 5 weeks after start of therapy. This case is discussed for its relevance to the use of lamotrigine which is currently prescribed very commonly in psychiatric practices.

Keywords: Hypersensitivity reaction, Lamotrigine, Stevens-Johnson syndrome

INTRODUCTION

Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are immune-complex-mediated hypersensitivity reactions that typically affects the skin and the mucous membranes leading to necrosis and sloughing of the epidermis. The most common etiology of SJS/TEN is hypersensitivity to certain drugs like, antibiotics, anticonvulsants and nonsteroid anti-inflammatories and allopurinol.1

Among anticonvulsants, SJS is rarely caused by lamotrigine, which is also used as a mood stabilizer.2 3 Various adverse effects associated with lamotrigine include headache, dizziness, somnolence, nausea, aggressiveness, insomnia and rash.4 The overall incidence of lamotrigine-induced serious rash is approximately 0.3 percent in adult patients with epilepsy receiving adjunctive therapy.5 Exact rates of Stevens-Johnson syndrome with lamotrigine are not known, but are reported as 0.02 percent in adults from the German Rash Registry.6 Though there has been a few reported cases of lamotrigine-induced SJS in Indian patients with epilepsy in combination with valproic acid, we can find no report of SJS in Indian patients of mood disorders on lamotrigine therapy without concomitant use of valproic acid.7

Here we report a rare case of lamotrigine-induced SJS in a 25 year old Indian patient suffering from Schizoaffective disorder. Use of the Naranjo algorithm scale indicated a probable relationship of causality with a score of 6.8
CASE REPORT

Patient is a 25 year old female housewife, resident of a rural area who has been suffering from schizoaffective disorder from 6 months and was prescribed haloperidol, divalproex sodium, lorazepam and metformin. After 4 months of therapy, lamotrigine 25 mg once daily was added to the regimen due to poor control of her symptoms. After about 5 weeks of lamotrigine therapy, the patient developed fever, chills, headache and rash over the whole body. She also became gradually intolerant to spicy food and developed oral lesions over a week. A week later, the patient was presented to our hospital.

On examination, erythematous maculopapular rash over her trunk and extremities were seen (Figures 1b, c and d). Bullous eruptions and detachment of epidermis on the face, haemorrhagic crusts over lips and erosion of mucous membrane inside her mouth were present (Figure 1a). Multiple genital lesions were also seen. She was admitted for further treatment and was kept under the care of a dermatologist, a gynaecologist and a psychiatrist.

DISCUSSION

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are severe idiosyncratic reactions with a reported incidence of around 2.6 to 6.1 cases per million people per year with a mortality rate of around 5%. SJS is named after two American paediatricians, Albert Mason Stevens and Frank Chalmbliss Johnson, who jointly published the first description of the disorder in the American Journal of Diseases of Children in 1922. SJS/TEN are immune-complex-mediated hypersensitivity reactions caused by certain drugs, infections and rarely, cancers. SJS/TEN characteristically involves skin and mucous membrane with painful eruptions and epidermal detachment.

Although several classification schemes have been reported, the simplest breaks the disease down as follows. Stevens-Johnson syndrome (SJS): A "minor form of TEN" with less than 10% body surface area (BSA) detachment. Overlapping Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): Detachment of 10-30% BSA. Toxic epidermal necrolysis (TEN): Detachment of more than 30% BSA.

SJS is a serious systemic disorder with the potential for severe morbidity and even death. Clinical features of SJS include involvement of skin and oral, nasal, eye, vaginal, urethral, gastrointestinal, and lower respiratory tract mucous membranes. Skin rash can begin as macules that develop into papules, vesicles, bullae, urticarial plaques or confluent erythema leading to edema, sloughing, blistering, ulceration and necrosis. Gastrointestinal and respiratory involvement may also progress to necrosis.

Medications are the leading trigger of SJS in adults. In addition to medications, conditions such as malignancies, systemic lupus erythematosus and viral infections may trigger SJS. Drug etiologies include reaction to antibiotics, antiepileptics, non-steroidal anti-inflammatory drugs, anti-malarial and allopurinol. SJS has also been associated with immunisation, e.g. measles and hepatitis B.

The pathogenesis of SJS is yet to be clarified. The scenario suggested by today's literature points toward drug-specific CD8+ cytotoxic T-cells utilizing perforin/granzyme B triggered apoptosis of epithelial cells. SJS has been reported from concomitant use of valproic acid and lamotrigine but reports of Lamotrigine alone causing SJS are relatively rare. Lamotrigine is a potential anti-epileptic drug which is also used as a mood stabilizer. Side effects of Lamotrigine generally include CNS symptoms like headache, sleep disturbance, movement disorder, hallucinations.

Figure 1: (a) Ulcerative lesions on lips and detachment of epidermis on the face; Erythematous maculopapular rash over (b) trunk (c) arms (d) thighs.
gastrointestinal symptoms like diarrhoea, nausea, vomiting, hepatic dysfunction and skin & cutaneous side effects like rash. Stevens-Johnson syndrome has also been mentioned as a rare hypersensitivity reaction/side effect of lamotrigine.

Though our patient was concomitantly on haloperidol since four months before the addition of lamotrigine to her drug regimen, it is unlikely that Haloperidol was the cause of her SJS because symptoms of SJS were seen 5 weeks after being on lamotrigine add-on therapy. Mechanisms for lamotrigine-induced SJS are less well understood but recent evidence suggests that antiepileptic drug-related hypersensitivity may be a consequence of chemotoxic and immunologically mediated injury; however, the pathogenesis of this reaction may vary somewhat among different antiepileptic drugs.20 We are reporting this case, since there is increasing use of lamotrigine in psychiatry (especially as a mood stabilizer) and because of the rarity of Stevens-Johnson syndrome (SJS) as an adverse effect of lamotrigine which can have very high mortality and morbidity.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94:419-36.
2. Sachs B, Rönnau AC, Schmiedeberg S, Ruzicka T, Gleichman E, Schuppe HC. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatol. 1997;195:60-4.
3. Keck PE, Mc Elroy SL. Anticonvulsants and antiepileptics in the treatment of bipolar disease. J Clin Psychiatr. 1998;59(6):74-81.
4. Parveen S, Javed MA. Stevens Johnson syndrome associated with lamotrigine. Pakistan J Med Sci. 2013;29(6):1450-2.
5. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions. Lancet. 1999;354:1033-4.
6. Messengill HS, Kustra RP, Messenheimer JA. Serious cutaneous reactions with antiepileptic drugs: adult and pediatric incidence estimates from registry and prescription data in Germany. Poster presentation at American Society of Health Systems Pharmacists Midyear Meeting, New Orleans, December 6-11, 2003.
7. Kavitha S, Anbuchelvan T, Mahalakshmi V. Stevens-Johnson syndrome induced by a combination of lamotrigine and valproic acid. J Pharm Bioallied Sci. 2015;7(2):S756-8.
8. Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.
9. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7(6):803-13.
10. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalma; report of two cases in children. Am J Dis Child. 1922;24:526-33.
11. Mockenhaupt M, Schopf E. Epidemiology of drug-induced severe skin reactions. Semion Cutan Med Surg. 1996;15(4):236-43.
12. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006;55(1):9-16.
13. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8(1):5.
14. Frittsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol. 2000;1(6):349-60.
15. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134-8.
16. Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Tareb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child. 2000;83(4):347-52.
17. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006;97:272-80.
18. Kavitha S, Anbuchelvan T, Mahalakshmi V. Stevens-Johnson syndrome induced by a combination of lamotrigine and valproic acid. J Pharm Bioallied Sci. 2015;7(2):S756-8.
19. Yalcin B, Karaduman A. Stevens Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol. 2000;43:898-9.
20. Naissbit DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111:1393-403.

Cite this article as: Kashyapa H, Verma L, Jadhav RB. Lamotrigine-induced Stevens-Johnson syndrome in a 25 year old lady. Int J Basic Clin Pharmacol 2016;5:2694-6.